Daxor Corporation (DXR)
NASDAQ: DXR · Real-Time Price · USD
12.35
+0.09 (0.69%)
At close: Feb 6, 2026, 4:00 PM EST
12.36
+0.01 (0.12%)
After-hours: Feb 6, 2026, 4:04 PM EST
Daxor Revenue
Daxor had revenue of $18.35K in the half year ending June 30, 2025, a decrease of -77.34%. This brings the company's revenue in the last twelve months to $66.31K, down -57.00% year-over-year. In the year 2024, Daxor had annual revenue of $119.71K, down -26.75%.
Revenue (ttm)
$66.31K
Revenue Growth
-57.00%
P/S Ratio
1,084.93
Revenue / Employee
$1,473
Employees
45
Market Cap
71.94M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 119.71K | -43.71K | -26.75% |
| Dec 31, 2023 | 163.42K | -68.22K | -29.45% |
| Dec 31, 2022 | 231.64K | -46.45K | -16.70% |
| Dec 31, 2021 | 278.09K | 13.65K | 5.16% |
| Dec 31, 2020 | 264.44K | -115.70K | -30.44% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| OraSure Technologies | 125.70M |
| Sanara MedTech | 101.88M |
| Pro-Dex | 72.10M |
| Stereotaxis | 30.08M |
| Precision Optics Corporation | 21.58M |
| Nephros | 17.93M |
| Ekso Bionics Holdings | 14.75M |
| Femasys | 2.06M |
DXR News
- 15 days ago - Daxor Corporation Announces $9 Million Registered Direct Offering - GlobeNewsWire
- 2 months ago - Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer - GlobeNewsWire
- 3 months ago - Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit - GlobeNewsWire
- 4 months ago - Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA - GlobeNewsWire
- 4 months ago - Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting - GlobeNewsWire
- 5 months ago - Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care - GlobeNewsWire
- 5 months ago - Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 5 months ago - Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter - GlobeNewsWire